Vibhuti Shah | Medicine and Dentistry | Best Researcher Award

Dr. Vibhuti Shah | Medicine and Dentistry | Best Researcher Award

MD, FRCPC at Mount Sinai Hospital, Canada

Dr. Vibhuti Shah is a distinguished neonatologist, clinical epidemiologist, and professor at the University of Toronto, with over two decades of expertise in pediatric research. She serves as Chair of the Research Ethics Board at Mount Sinai Hospital and has played a pivotal role in advancing neonatal care through her extensive research. Holding multiple prestigious qualifications, including an MSc in Clinical Epidemiology, MRCPCH (UK), and FRCPC (Canada), she has been recognized internationally for her contributions, receiving awards such as the Patil Award (AMEE, UK) and invitations from JAMA’s “Author in the Room” program. Dr. Shah’s leadership in academia and research ethics, combined with her mentorship of future medical professionals, underscores her commitment to improving neonatal outcomes. Her work has significantly impacted clinical guidelines and patient care, making her a strong contender for the Best Researcher Award. Her dedication to research excellence continues to shape advancements in neonatology and pediatrics globally.

Professional Profile

Education

Dr. Vibhuti Shah has an extensive educational background in medicine, pediatrics, and clinical research. She earned her MBBS from the University of Bombay in 1982, followed by a Diploma in Child Health (DCH) in 1986 and an MD in Pediatrics in 1987. Further advancing her expertise, she obtained the prestigious MRCP (UK) in 1994 and MRCPCH (UK) in 1997, signifying her specialization in pediatrics and child health. She later achieved the FRCPC (Paediatrics) from the Royal College of Physicians and Surgeons of Canada in 2005, cementing her reputation in the field. Committed to research excellence, Dr. Shah pursued an MSc in Clinical Epidemiology and Healthcare Research at the University of Toronto in 2007. Her extensive training includes fellowships in neonatology and perinatal medicine in India, the UK, and Canada. This strong academic foundation has enabled her to contribute significantly to neonatal research, ethics, and healthcare advancements.

Professional Experience

Dr. Vibhuti Shah has an extensive professional career spanning clinical practice, research, and academic leadership in neonatology and pediatrics. She is a Professor in the Department of Pediatrics and the Institute of Health Policy, Management, and Evaluation at the University of Toronto and a Staff Neonatologist and Clinical Epidemiologist at Mount Sinai Hospital. She also chairs the Research Ethics Board at Mount Sinai Hospital and Humber River Hospital, overseeing research integrity and compliance. Previously, she served as Interim Co-Chair of the Research Ethics Board and held clinical fellowships in neonatology in Canada, the UK, and India. She has been an Associate Member of the School of Graduate Studies at the University of Toronto since 2008 and has contributed significantly to mentoring and training medical professionals. With decades of experience in research, clinical care, and ethics, Dr. Shah has played a vital role in shaping neonatal healthcare policies and advancing pediatric medicine.

Research Interest

Dr. Vibhuti Shah’s research interests focus on neonatal-perinatal medicine, clinical epidemiology, and healthcare ethics, with a strong emphasis on improving neonatal outcomes through evidence-based interventions. She has conducted extensive research on pain management in neonates, neonatal resuscitation, and perinatal care strategies, contributing to clinical guidelines that enhance patient care. Her work in clinical epidemiology involves evaluating healthcare interventions, systematic reviews, and meta-analyses to improve neonatal and pediatric care practices. As Chair of the Research Ethics Board at Mount Sinai Hospital, she is also deeply engaged in research ethics, ensuring the ethical conduct of clinical trials and healthcare studies. Additionally, Dr. Shah has been involved in health policy research, focusing on optimizing neonatal healthcare delivery. Her contributions, recognized by prestigious international awards, continue to shape neonatal clinical practices and influence medical education, making a significant impact on global pediatric research and patient care.

Award and Honor

Dr. Vibhuti Shah has received numerous prestigious awards and honors in recognition of her contributions to neonatal research, medical education, and clinical epidemiology. Internationally, she was awarded the Patil Award by the Association for Medical Education in Europe (AMEE, UK) for her work in teaching and learning. She was also selected for the Mid-Atlantic Conference on Perinatal Research in both 2005 and 2006, receiving travel awards for her groundbreaking research in neonatology. In 2006, she was honored with the Thomas Jefferson Honorarium and Speakership for her clinical research contributions. Additionally, she was selected by the Journal of the American Medical Association (JAMA) for its “Author in the Room” program, recognizing her impactful research on neonatal pain management. These accolades underscore Dr. Shah’s exceptional leadership, innovation, and commitment to advancing neonatal healthcare, making her a highly respected figure in the global pediatric research community.

Research Skill

Dr. Vibhuti Shah possesses a diverse set of research skills that have significantly contributed to advancements in neonatal-perinatal medicine and clinical epidemiology. She is highly proficient in clinical trial design, systematic reviews, meta-analyses, and evidence-based medicine, ensuring that neonatal healthcare practices are guided by robust scientific evidence. Her expertise in biostatistics and data analysis allows her to critically evaluate healthcare interventions and contribute to policy changes. As Chair of the Research Ethics Board at Mount Sinai Hospital, she has extensive experience in research ethics, protocol development, and regulatory compliance, ensuring the integrity of clinical studies. Dr. Shah is also skilled in grant writing, peer-reviewed publishing, and mentoring young researchers, fostering innovation in pediatric research. Her ability to integrate clinical epidemiology with neonatology has led to impactful findings that have shaped neonatal care guidelines, demonstrating her strong analytical, ethical, and leadership capabilities in research.

Conclusion

Dr. Vibhuti Shah is an exceptionally strong candidate for the Best Researcher Award due to her outstanding contributions to neonatology, clinical epidemiology, and medical ethics research. While she has already earned international recognition, additional emphasis on research impact metrics and global collaboration could make her case even stronger.

Publications Top Noted

  1. Shah VK, Firmal P, Alam A, Ganguly D, Chattopadhyay S. (2020). Overview of immune response during SARS-CoV-2 infection: lessons from the past. Frontiers in Immunology, 11, 1949. https://pubmed.ncbi.nlm.nih.gov/32849654
    Cited by: 548

  2. Firmal P, Shah VK, Chattopadhyay S. (2020). Insight into TLR4-mediated immunomodulation in normal pregnancy and related disorders. Frontiers in Immunology, 11, 807.
    Cited by: 105

  3. Pant R, Firmal P, Shah VK, Alam A, Chattopadhyay S. (2021). Epigenetic regulation of adipogenesis in development of metabolic syndrome. Frontiers in Cell and Developmental Biology, 8, 619888.
    Cited by: 52

  4. Choksi A, Parulekar A, Pant R, Shah VK, Nimma R, Firmal P, Singh S, et al. (2021). Tumor suppressor SMAR1 regulates PKM alternative splicing by HDAC6-mediated deacetylation of PTBP1. Cancer & Metabolism, 9, 1-17.
    Cited by: 23

  5. Alam A, Taye N, Patel S, Thube M, Mullick J, Shah VK, Pant R, et al. (2019). SMAR1 favors immunosurveillance of cancer cells by modulating calnexin and MHC I expression. Neoplasia, 21(10), 945-962.
    Cited by: 19

  6. Firmal P, Shah VK, Pant R, Chattopadhyay S. (2022). RING finger protein TOPORS modulates the expression of tumor suppressor SMAR1 in colorectal cancer via the TLR4‐TRIF pathway. Molecular Oncology, 16(7), 1523-1540.
    Cited by: 6

  7. Pant R, Alam A, Choksi A, Shah VK, Firmal P, Chattopadhyay S. (2021). Chromatin remodeling protein SMAR1 regulates adipogenesis by modulating the expression of PPARγ. Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids.
    Cited by: 3

  8. Sharma A, Garg S, Shah V, Agrawal P, Lohan P. (2015). Basics of design: lessons from walled city of Jaipur.
    Cited by: 2

Liying Zhang | Medicine and Dentistry | Best Researcher Award

Dr. Liying Zhang | Medicine and Dentistry | Best Researcher Award

Professor at University of California, Los Angeles, United States

Dr. Liying Zhang, MD, PhD, FACMG, is a distinguished researcher and professor specializing in molecular diagnostics and precision oncology. She serves as the Director of the Advanced Molecular Diagnostics Service at UCLA David Geffen School of Medicine and the Director of Cancer Molecular Diagnostics at UCLA Jonsson Comprehensive Cancer Center. With extensive experience in molecular genetics, her research focuses on cancer diagnostics, biomarker discovery, and precision medicine. She has contributed to numerous high-impact studies, secured significant research funding, and played an active role in national and international expert committees. Her expertise spans clinical molecular genetics, genomics, bioinformatics, and laboratory medicine, making her a leading figure in the field of cancer molecular diagnostics.

Professional Profile 

Education

Dr. Zhang earned her Ph.D. in Biochemistry and Molecular Biology from The Johns Hopkins University in 2003, alongside a Master’s degree in Computer Science with a focus on Bioinformatics in 2002. She obtained her MD from Peking University, Beijing, China, in 1994. She holds multiple clinical licensures and board certifications, including Clinical Molecular Genetics and Genomics from the American Board of Medical Genetics and Genomics. Her strong educational foundation in medicine, biochemistry, molecular biology, and computational science has equipped her with the interdisciplinary expertise required for advancing molecular diagnostics and precision medicine.

Professional Experience

Dr. Zhang has held several prestigious roles in molecular pathology and diagnostics. Since 2020, she has been a Professor and Director at UCLA, leading advanced molecular diagnostics initiatives. Previously, she served as a Director and Molecular Geneticist at Memorial Sloan Kettering Cancer Center from 2005 to 2019, overseeing diagnostic molecular genetics laboratories and contributing to groundbreaking cancer research. Her earlier roles include research positions at the National Research Institute for Family Planning in China. Additionally, she has been actively involved in professional committees, journal reviews, and mentorship programs, furthering advancements in molecular diagnostics and genetic research.

Research Interest

Dr. Liying Zhang’s research focuses on molecular diagnostics, cancer genomics, and precision oncology. She is dedicated to identifying genetic biomarkers that enhance cancer detection, prognosis, and treatment strategies. Her work involves integrating next-generation sequencing (NGS) technologies, bioinformatics, and molecular pathology to improve the accuracy and efficiency of cancer diagnostics. She is particularly interested in the molecular mechanisms underlying tumor development, drug resistance, and targeted therapies. Through collaborations with oncologists, geneticists, and data scientists, she aims to translate genetic findings into clinically actionable insights that improve patient outcomes. Her research also extends to liquid biopsy, epigenetics, and the development of novel molecular assays for early cancer detection.

Awards and Honors

Dr. Zhang has received numerous prestigious awards recognizing her contributions to molecular genetics and cancer diagnostics. She has been honored as a Fellow of the American College of Medical Genetics and Genomics (FACMG), acknowledging her leadership and expertise in clinical molecular genetics. She has also received research excellence awards from institutions such as Memorial Sloan Kettering Cancer Center and UCLA for her groundbreaking work in cancer molecular diagnostics. Additionally, she has been an invited speaker at leading international conferences, including the American Society of Human Genetics (ASHG) and the Association for Molecular Pathology (AMP). Her contributions to scientific research and clinical practice have earned her recognition as a thought leader in precision medicine and molecular oncology.

Research Skills

Dr. Zhang possesses a diverse range of research skills in molecular diagnostics and genomics. She is proficient in next-generation sequencing (NGS) technologies, whole-genome and transcriptome analysis, and single-cell sequencing. She has extensive experience in bioinformatics, data mining, and computational modeling for genetic variant interpretation. Her expertise includes designing and validating molecular assays for clinical diagnostics, including PCR-based and hybrid capture-based sequencing methods. She is also skilled in laboratory management, regulatory compliance, and quality control in clinical molecular genetics laboratories. Additionally, her strong background in translational research allows her to bridge the gap between basic scientific discoveries and clinical applications, ensuring that her findings have a direct impact on patient care and personalized treatment strategies.

Conclusion

Dr. Liying Zhang is highly suitable for the Best Researcher Award due to her exceptional contributions to molecular diagnostics, cancer genomics, and precision medicine. Her extensive experience in research leadership, grant acquisition, and clinical applications makes her an outstanding candidate. Strengthening her independent research leadership and international collaborations would further solidify her candidacy for this prestigious award.

Publications Top Noted

  • Title: Inherited DNA-repair gene mutations in men with metastatic prostate cancer
    Authors: CC Pritchard, J Mateo, MF Walsh, N De Sarkar, W Abida, H Beltran, …
    Year: 2016
    Citation: 1765

  • Title: Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer
    Authors: L Klotz, L Zhang, A Lam, R Nam, A Mamedov, A Loblaw
    Year: 2010
    Citation: 1402

  • Title: Long-term follow-up of a large active surveillance cohort of patients with prostate cancer
    Authors: L Klotz, D Vesprini, P Sethukavalan, V Jethava, L Zhang, S Jain, …
    Year: 2015
    Citation: 1399

  • Title: CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct
    Authors: IYL Tan, AM Demchuk, J Hopyan, L Zhang, D Gladstone, K Wong, …
    Year: 2009
    Citation: 792

  • Title: Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance
    Authors: J Holzbeierlein, P Lal, E LaTulippe, A Smith, J Satagopan, L Zhang, …
    Year: 2004
    Citation: 708

  • Title: Microsatellite instability is associated with the presence of Lynch syndrome pan-cancer
    Authors: A Latham, P Srinivasan, Y Kemel, J Shia, C Bandlamudi, D Mandelker, …
    Year: 2019
    Citation: 591

  • Title: Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
    Authors: W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, …
    Year: 2017
    Citation: 583

  • Title: Celiac disease: summary
    Authors: A Rostom, C Dubé, A Cranney, N Saloojee, R Sy, C Garritty, M Sampson, …
    Year: 2004
    Citation: 511

  • Title: Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing
    Authors: D Mandelker, L Zhang, Y Kemel, ZK Stadler, V Joseph, A Zehir, …
    Year: 2017
    Citation: 508

  • Title: Tumour lineage shapes BRCA-mediated phenotypes
    Authors: P Jonsson, C Bandlamudi, ML Cheng, P Srinivasan, SS Chavan, …
    Year: 2019
    Citation: 384

  • Title: Hereditary diffuse gastric cancer: updated clinical practice guidelines
    Authors: VR Blair, M McLeod, F Carneiro, DG Coit, JL D’Addario, JM van Dieren, …
    Year: 2020
    Citation: 381

  • Title: Update of the international consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases
    Authors: E Chow, P Hoskin, G Mitera, L Zeng, S Lutz, D Roos, C Hahn, …
    Year: 2012
    Citation: 374

  • Title: Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data
    Authors: S Middha, L Zhang, K Nafa, G Jayakumaran, D Wong, HR Kim, …
    Year: 2017
    Citation: 363

  • Title: Genetic predictors of response to systemic therapy in esophagogastric cancer
    Authors: YY Janjigian, F Sanchez-Vega, P Jonsson, WK Chatila, JF Hechtman, …
    Year: 2018
    Citation: 352